卡瑞利珠单抗联合标准化疗一线治疗不可手术食管鳞癌的临床效果OA
Clinical Effect of Carrilizumab Combined with Standard Chemotherapy in First-line Treatment of Inoperable Esophageal Squamous Cell Carcinoma
目的:探讨卡瑞利珠单抗联合标准化疗一线治疗不可手术食管鳞癌的临床效果.方法:选取 2022 年 6 月—2023 年 6 月在泰安市立医院接受治疗的 100 例食管鳞癌患者为研究对象,并按随机数表法分为两组,每组各 50 例.标准组患者给予顺铂联合紫杉醇治疗,联合组则在标准组的基础上给予卡瑞利珠单抗治疗.比较两组患者的临床疗效、实验室指标[癌胚抗原(CEA)、血管内皮生长因子(VEGF)、鳞状细胞癌相关抗原(SCC-Ag)]、免疫功能相关指标(CD3+、CD4+、CD4+/CD8+)及不良反应发生情况.结果:联合组的疾病控制率为 75.56%,高于标准组 55.56%,差异有统计学意义(P<0.05);治疗后,两组患者的实验室指标均低于本组治疗前,且联合组低于标准组,差异有统计学意义(P<0.05);治疗后,两组患者免疫功能相关指标均高于本组治疗前,且联合组高于标准组,差异有统计学意义(P<0.05);两组患者不良反应比较,差异无统计学意义(P>0.05).结论:卡瑞利珠单抗联合标准化疗一线治疗不可手术食管鳞癌,可有效降低患者血清CEA、VEGF、SCC-Ag水平,改善患者免疫水平,提高抗肿瘤效果,减少不良反应.
Objective:To investigate the clinical effect of carrilizumab combined with standard chemotherapy in the first-line treatment of inoperable esophageal squamous cell carcinoma.Method:100 patients with esophageal squamous cell carcinoma who received treatment in the hospital from June 2022 to June 2023 were selected as the study objects and divided into two groups according to random number table method,with 50 cases in each group.Patients in the standard group were treated with cisplatin combined with paclitaxel,and patients in the combined group were treated with carrilizumab on the basis of the standard group.The clinical efficacy,laboratory indicators(CEA,VEGF,SCC-Ag),immune function related indicators(CD3+,CD4+,CD4+/CD8+)and adverse reactions were compared between the two groups.Result:The disease control rate of combined group was 75.56%,higher than 55.56%of standard group,(P<0.05).After treatment,the laboratory indexes of 2 groups were lower than those before treatment,and the combined group was lower than the standard group,(P<0.05).After treatment,the related indexes of immune function in 2 groups were higher than those before treatment,and the combined group was higher than the standard group,(P<0.05).There was no significant difference in adverse reactions between the two groups.Conclusion:Carrellizumab combined with standard chemotherapy in first-line treatment of inoperable esophageal squamous cell carcinoma can effectively reduce the levels of serum CEA,VEGF and SCC-Ag,improve the immune level of patients,and enhance the anti-tumor effect without increasing adverse reactions.
秦立东;张凯利;乔辉;张洪伟;王艳秋
泰安市立医院 山东 泰安 271200
卡瑞利珠一线治疗标准化疗食管鳞癌
Carelli beadsFirst-line treatmentStandard chemotherapyEsophageal squamous cell carcinoma
《中外医学研究》 2024 (021)
21-24 / 4
泰安市立医院科研项目(ZD202202)
评论